ArticleHealth science reports2026
Weight-Reduction and Safety Profile of Once-Weekly Non-Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real-World Retrospective Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.Diabetes, obesity & metabolism · 2026Review
- Weight-Reduction and Safety Profile of Once-Weekly Non-Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real-World Retrospective Study.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Semaglutide, a once-weekly injectable glucagon-like peptide, showed double-digit weight reduction with an acceptable safety profile in clinical trials and real-world studies. The efficacy and safety of non-comparable biotherapeutic (NCB) semaglutide are not adequately reported. Our study aimed to assess the weight reduction and adverse effects of an NCB semaglutide in a real-world setting. Methods: This retrospective observational study conducted at three urban private practice settings collected data from an electronic record of 87 people with obesity [age (years): 32.2 ± 11.6, BMI (kg/m Results: The maximum prescribed doses of NCB semaglutide were 0.5 mg per week in 65 (74.7%) of participants, followed by 1.0 mg and 1.7 mg per week in 17 (19.5%) and 5 (5.7%) participants, respectively. Considering available participants of all visits ( Conclusion: A locally available NCB semaglutide in an uncontrolled, real-world setting showed acceptable weight loss and safety profiles among people with obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.